10x Genomics (TXG) | Stock Overview & Key Data
10x Genomics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $208.99 on June 28, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
10x Genomics
TXG
|
2.82B Mid-cap | 10.42% | 51.98% | 93.05% | 104.44% | 93.86% | 177.04% | -50.37% | -85.17% | -44.82% | -44.82% | -44.82% |
|
Ge Healthcare
GEHC
|
31.89B Large-cap | 0.14% | 6.58% | -10.27% | -23.32% | -21.81% | -9.79% | -17.13% | 14.87% | 14.87% | 14.87% | 14.87% |
|
Veeva Systems
VEEV
|
26.49B Large-cap | -3.03% | 2.08% | -12.47% | -26.32% | -26.12% | -43.54% | -20.25% | -47.98% | 374.26% | 259.41% | 259.41% |
|
Tempus AI
TEM
|
9.35B Mid-cap | 7.68% | 19.10% | 2.83% | -23.81% | -16.10% | -32.91% | 18.81% | 18.81% | 18.81% | 18.81% | 18.81% |
|
BrightSpring Health
BTSG
|
9.30B Mid-cap | 8.21% | 10.67% | 64.10% | 78.20% | 66.88% | 198.54% | 474.82% | 474.82% | 474.82% | 474.82% | 474.82% |
|
HealthEquity
HQY
|
6.57B Mid-cap | -0.99% | 5.84% | 10.55% | -9.17% | -4.50% | -15.67% | 41.37% | 14.18% | 203.78% | 421.18% | 421.18% |
Ownership & Short Interest
Calculate Your 10x Genomics Investment Returns
Long-Term Investment Performance Analysis
10x Genomics stock price in Sep 2019 was $52.27, A $1,000.00 lump sum investment in 10x Genomics made 6 years ago would be worth approximately $616.41 today, representing a negative return of -38.36%. This translates to an annualized return (CAGR) of -6.90%.
6 Years 9 Months Investment Scenario (Sep 2019 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is TXG's 52-week high and low?
- In the last 52 weeks, 10x Genomics reached a high of $35.65 (on June 4, 2026) and a low of $10.17 (on June 16, 2025).
- What is the market cap and P/E ratio for TXG?
- Curious about 10x Genomics's size and valuation? Its market capitalization stands at 2.82B. When it comes to valuation, the P/E ratio (trailing twelve months) is -63.09, and the forward P/E (looking ahead) is 110.40.
- Does TXG pay dividends? If so, what's the yield?
- As for dividends, 10x Genomics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are 10x Genomics's main competitors or similar companies to consider before investing?
When looking at 10x Genomics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Ge Healthcare
GEHC31.89B Healthcare Health Information Services -9.79% -17.13% Veeva Systems
VEEV26.49B Healthcare Health Information Services -43.54% -20.25% Tempus AI
TEM9.35B Healthcare Health Information Services -32.91% 18.81% BrightSpring Health
BTSG9.30B Healthcare Health Information Services 198.54% 474.82% HealthEquity
HQY6.57B Healthcare Health Information Services -15.67% 41.37% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for 10x Genomics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of 10x Genomics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -5.78%, the Debt to Equity ratio from the most recent quarter is 10.59, and its Gross Profit Margin stands at 68.09%.
- What is the recent revenue and earnings growth for TXG?
- Looking at 10x Genomics's growth, its revenue over the trailing twelve months (TTM) was $643M. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.60%, and quarterly earnings saw a YoY growth of 0.61%.
- How much of TXG stock is held by insiders and institutions?
- Wondering who owns 10x Genomics stock? Company insiders (like executives and directors) hold about 1.81% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 108.01%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.